has been cited by the following article(s):
[1]
|
Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer
|
|
Chronobiology International,
2017 |
|
|
[2]
|
Cell‐Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta‐Analysis
|
|
2017 |
|
|
[3]
|
Papel das biopsias líquidas no cancro esofágico, gástrico, pancreático e colo-retal
|
|
Dissertation, Open Repository of the University of Porto,
2017 |
|
|
[4]
|
Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer
|
|
PloS one,
2015 |
|
|
[5]
|
Response to comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
|
|
Br J Cancer,
2014 |
|
|
[6]
|
Cell‐free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer
|
|
International journal of cancer,
2014 |
|
|
[7]
|
Gemcitabine and Capecitabine for Heavily Pre-treated Metastatic Colorectal Cancer Patients–A Phase II and Translational Research Study
|
|
Anticancer …,
2014 |
|
|
[8]
|
Reply to 'Comment on KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
|
|
British journal of …,
2014 |
|
|
[9]
|
Cell‐free DNA in healthy individuals, non‐cancerous disease and strong prognostic value in colorectal cancer
|
|
International Journal of Cancer,
2014 |
|
|
[10]
|
Comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
|
|
British journal of cancer,
2014 |
|
|
[1]
|
Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer
Acta Oncologica,
2017
DOI:10.1080/0284186X.2016.1253861
|
|
|
[2]
|
Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer
PLOS ONE,
2015
DOI:10.1371/journal.pone.0108247
|
|
|
[3]
|
Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer
International Journal of Cancer,
2014
DOI:10.1002/ijc.28946
|
|
|
[4]
|
Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’
British Journal of Cancer,
2014
DOI:10.1038/bjc.2014.115
|
|
|